Hansa Biopharma AB

Address: P. O. Box 785

Sponsor Overview

assignment

Specializations

Autoimmune Kidney Disease

Clinical research includes anti-GBM antibody disease (Goodpasture disease), with interest in severe glomerular injury and immune-mediated loss of kidney function.

Anti-GBM antibody disease
Goodpasture disease
Kidney function

The therapeutic focus in this area is on conditions where pathogenic antibodies drive rapid renal damage.

Kidney Transplant Desensitisation

Research activity also centres on highly sensitised patients awaiting kidney transplantation, including those with a positive crossmatch against a potential donor.

Highly sensitised patients
Crossmatch conversion
Kidney transplant list

This area reflects a strong therapeutic interest in enabling transplantation for patients with limited donor compatibility.

Paediatric Transplant Medicine

The sponsor funds studies in highly sensitised paediatric patients with donor-specific antibodies affecting access to transplantation.

Paediatric kidney transplantation
Living donor
Deceased donor

These trials place emphasis on transplant access in children with complex immunological barriers.

Graft Survival and Long-Term Transplant Outcomes

Additional research addresses graft failure-free survival after imlifidase administration in kidney transplant recipients, including follow-up in previously treated cohorts.

Graft failure-free survival
Imlifidase
Post-transplant follow-up

Studies in this domain are focused on transplant durability and outcomes in patients with challenging immunological profiles.

Sponsored Trials

Trial Name	Country	Status
A Phase 3 open-label, controlled, randomised, multi-centre trial comparing imlifidase and standard-of-care with standard-of-care alone in the treatment of severe anti-GBM antibody disease (Goodpasture disease)	Austria Belgium Czechia Denmark France Germany Ireland Italy Poland Spain Sweden The Netherlands	Not Recruiting
A prospective, post-authorisation long-term follow up trial of patients previously treated with imlifidase prior to kidney transplantation, including a non-comparative concurrent reference cohort	Austria Belgium Czechia France Italy Spain Sweden The Netherlands	Not Recruiting
A single-arm, multi-centre trial to evaluate efficacy and safety of imlifidase in highly sensitised children (1-17 years) receiving a kidney transplant with positive crossmatch against a living or deceased donor converted to negative after imlifidase treatment	Finland France Spain Sweden	Recruiting
Efficacy and Safety of Imlifidase in Desensitizing Highly Sensitized End-Stage CKD Patients for Kidney Transplantation with Positive Crossmatch	Austria Belgium Czechia France Germany Italy Slovenia Spain Sweden The Netherlands	Not Recruiting